I will post my GvHD post here too.

Below this is how I knew Pestell was the guy. I liked Dr. Burger, but this was a brilliant way for RP to tackle the GvHD trial problem: perfect strategy, answer, and solution

BTW, while on the topic, didn't they randomly inject 10 for GvHD, leronlimab vs placabo back in 2018? Since the change the study to all leronlimab assumable because of the good results with leronlimab making it unethical to use a placabo; maybe one day we will get to see those results.

Here is the animal study using leronlimab for GvHD

https://www.bbmt.org/article/S1083-8791(17)30810-8/fulltext

and maraviroc trial results
https://www.sciencedirect.com/science/article...9118306013


NobleCon at 37:00

RP

Quote:

---

In terms of the graft-versus-host disease study, which we intend to reopen, the plan here is to change the entry criterion. That said that's the only significant change in the way in which the study is designed and the i ntent here is to include only the low dose radiation priming group of patients and have a common conditioning regimen for the patients. Before there was a lot of different conditioning regimens and it's very hard to see a difference when everyone comes to you with a different background treatment. So my intent was to meet with all of the thought leaders all the principal investigators. Having met with them all over the last couple of months, get a consensus around what a common conditioning regimen would be that and the selection criterion has now been modified so the intent would be to reopen that study. Again, this is a 14 week study in GVHD. So we're not talking about two years. This is a 14 week study and I think it's important to emphasize in the cancer space the bar is set at quite a different level to HIV. 14 week study in GVHD

---